89bio
ETNB
ETNB was delisted on the 29th of October, 2025.
145 hedge funds and large institutions have $1.08B invested in 89bio in 2023 Q1 according to their latest regulatory filings, with 60 funds opening new positions, 48 increasing their positions, 29 reducing their positions, and 20 closing their positions.
200% more first-time investments, than exits
New positions opened: 60 | Existing positions closed: 20
122% more call options, than puts
Call options by funds: $55.5M | Put options by funds: $25M
84% more capital invested
Capital invested by funds: $589M → $1.08B (+$492M)
66% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 29
37% more funds holding
Funds holding: 106 → 145 (+39)
3.15% more ownership
Funds ownership: 99.5% → 102.65% (+3.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$38.7M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$35.6M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$32.1M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$30.7M |
| 5 |
SCM
Suvretta Capital Management
New York
|
+$28.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$46.6M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$26.7M |
| 3 |
CC
Commodore Capital
New York
|
-$9.65M |
| 4 |
Walleye Capital
New York
|
-$6.11M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$5.78M |
ETNB Hedge Fund Activity: Q1 2023 in Review
145 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in 89bio (ETNB) for Q1 2023, worth a combined $1.08B — up 84% from $589M a quarter earlier.
Buyers outnumbered sellers: 60 funds opened new ETNB positions and 20 closed out — a net gain of 40 holders — while 48 added to existing stakes and 29 trimmed.
The largest buyer was State Street, adding an estimated $38.7M. The largest seller was OrbiMed, exiting entirely with an estimated $46.6M sold.
- 145 institutional investors held 89bio (ETNB) as of Q1 2023, up from 106 in Q4 2022.
- Funds reported $1.08B of 89bio stock for Q1 2023, up 84% quarter-over-quarter.
- 60 funds opened new 89bio positions in Q1 2023 and 20 closed out, a net change of +40 holders.
- The largest 89bio buyer in Q1 2023 was State Street, an estimated $38.7M added.
- The largest 89bio seller in Q1 2023 was OrbiMed, an estimated $46.6M sold.
Based on aggregated 13F filings for Q1 2023.